Navigation Links
Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor
Date:7/21/2014

loq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bispecific therapeutic antibodies, and ADCs.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements  
This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about commencing its Cynviloq registrational trial; and the advances made in developing human monoclonal antibodies, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Acknowledgement of NIH Support 
The project described above is supported by Award Numbe
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
2. Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
3. Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
4. Sorrento Therapeutics Adopts Stockholder Rights Plan
5. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
6. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
7. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
8. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
9. Sorrento Therapeutics Completes IgDraSol Merger
10. Sorrento Therapeutics to Present at Two Healthcare Conferences
11. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  Heska Corporation (Nasdaq: HSKA ) announces ... Its Third Quarter 2014 Earnings Conference Call on the ... 11:00 a.m. (EDT)Where: , www.heska.com (click on ... page of this website)How:Live over the Internet -- Simply ... Alternatively, you may use the following teleconference access numbers:  ...
(Date:10/25/2014)... Md. , Oct. 24, 2014  The ... highlighted the latest results achieved by ... system. The National Precursor Log ... at the point of sale and helps flag ... narcotics agents often set up NPLEx "watch lists" ...
(Date:10/25/2014)... Metanome, Inc. , a Houston -based ... the genomic sequencing provider for Seres Health,s ( ... SER 109, an Ecobiotic® therapeutic for the treatment of ... Metanome has provided genomic sequencing services in ... genomic characterization has enabled the study of the microbiota ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2
... FORD, Pa., Oct. 12, 2011 Endo Pharmaceuticals (Nasdaq: ... results on October 27, 2011 and will host a conference ... discuss these results.   David P. Holveck, president ... Ivan Gergel, executive vice president of R&D, Alan Levin, executive ...
... Aircraft Medical ("Aircraft"), the UK medical devices company, today ... Covidien (NYSE: COV ), a leading global ... billion, and 41,000 employees worldwide. Under the ... Aircraft,s proprietary McGRATH ® MAC video laryngoscope in ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2Aircraft Medical Signs Multinational Distribution Agreement with Covidien for McGRATH® MAC Video Laryngoscope 2
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the Connecticut ... the field of establishing recovery community organizations. Bob had ... he retired, he set out to answer a couple questions ... , 1. Where are the people in recovery when ... Can the recovery community be organized to advocate for issues ...
(Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... spot increased risks for certain cancers, one might think that ... But a new study suggests that, at least with colon ... their genes doubled their risk of colon cancer were no ... "It didn,t make any difference, not at all," said ...
(Date:10/22/2014)... 22, 2014 Medical Solutions ... is happy to announce that our co-founder and ... Industry Analysts’ Staffing 100 for 2014. Anderson was ... most influential people in the staffing industry,” in ... the 13th-largest healthcare staffing company in the U.S., ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3
... Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company,(Nasdaq: ... filed an Abbreviated New,Drug Application (ANDA) for over-the-counter ... a generic version of Monistat(R) 1,Combination Pack. The ... file an ANDA,with a Paragraph IV certification against ...
... CLEARWATER, Fla., April 21 Lincare Holdings,Inc. (Nasdaq: ... respiratory,therapy services delivered to patients in the home, today ... 2008., For the quarter ended March 31, 2008, ... $378.5 million for the first quarter of 2007.,The Company ...
... 21 In honor of their 25th,anniversary, Sierra Tucson ... April 30, 2008, from 8:30 -- 10:00 a.m. at ... S. Doheny Drive, Los,Angeles, CA 90048. Over 200 attendees ... their peers., Among those being recognized for their ...
... People with scalp or neck melanomas die at nearly ... body, including the face or ears, researchers at the University ... analysis of 51,704 melanoma cases in the U.S. confirms that ... Those with scalp or neck melanomas die at a rate ...
... enforcement agencies intensifying focus on hospital-physician ... ... /PRNewswire/ - The Deloitte Forensic Center reports,that complying with ... hospitals. Almost all physicians have ethical, mutually,beneficial relationships with ...
... West Nile Virus and Other Diseases, SACRAMENTO, Calif., ... hand. Coinciding with the launch of mosquito season, the,California ... April 25,2008 West Nile Virus and Mosquito and Vector ... mosquito-borne disease that can result in,debilitating cases of meningitis ...
Cached Medicine News:Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 2Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 3Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 5Health News:Most lethal melanomas are on scalp and neck 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 3Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 4Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 5Health News:State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week 2
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for directing a flexible tipped wire guide in the ureter. The angled tip allows passage of the catheter past a ureteral stone in preparation for E.S.W.L. Supplied sterile in peel-open packages. ...
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
Medicine Products: